Passage Bio (PASG) Earnings Date & Reports

Key Takeaways

• Passage Bio (PASG) is expected to report its third-quarter 2026 results in the coming days, with a conference call scheduled for November 10, 2026, at 9:30 a.m. ET.
• Wall Street consensus for the quarter points to a GAAP (Generally Accepted Accounting Principles) loss per share of roughly $2.43 to $2.44, with revenue again expected at $0 following the wind-down of its gene therapy programs.
• Investors are closely watching the company's cash position, which stood at about $24.2 million at the end of the second quarter and triggered a going-concern disclosure.
• The pending merger with Remix Therapeutics, expected to close in the fourth quarter of 2026, remains the central catalyst overshadowing near-term results.
• Passage Bio's last two quarters have met or beaten consensus on EPS, but with limited operating activity, the earnings surprise matters less than balance-sheet and deal updates.
• For more context on the stock's Major News, Today's Price Move, Price Targets, and Forecast, explore these additional pages.
• You can also explore Trending AI Robots for AI-driven market insights and trading signals.

Earnings Context and Why It Matters

Passage Bio, a clinical-stage genetic medicines company, has largely transitioned from developing gene therapies to pursuing a strategic merger with Remix Therapeutics. That pivot makes its quarterly earnings less about top-line growth and more about capital preservation. With all gene therapy programs wound down and revenue at zero, the report serves as a checkpoint on how efficiently the company is managing its remaining cash ahead of an expected fourth-quarter merger close. For investors, the key questions are whether the company's cash runway remains sufficient to reach deal completion and whether management updates the timeline or terms of the transaction. The results also offer a window into lingering restructuring costs and any final program-related expenses.

Earnings Expectations

Analysts expect Passage Bio to report a GAAP loss per share in the range of approximately $2.43 to $2.44 for the third quarter of 2026, a period ending September 30, 2026, under its standard calendar fiscal year. Revenue is projected at $0, consistent with the company's decision to halt its development-stage programs. For context, the company reported a loss of $2.44 per share in the prior quarter, matching consensus, and a loss of $2.36 per share in the first quarter of 2026, beating estimates by roughly 18%. A year earlier, third-quarter 2025 EPS came in at -$2.44, beating the consensus estimate of -$2.84 by about 14%. With no meaningful revenue stream, the per-share figure primarily reflects operating expenses, interest income, and one-time items such as lease-termination gains or restructuring charges.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening. For investors tracking pre-revenue biotechnology names like Passage Bio, it offers a structured way to compare companies across the sector and surface actionable signals.

Market Reaction and Investor Sentiment

Sentiment heading into the report is shaped less by earnings expectations than by the pending Remix Therapeutics merger. Because Passage Bio has no product revenue and minimal operating activity, investors are unlikely to react strongly to the headline loss per share. Instead, the market is expected to focus on any commentary regarding the merger's closing timeline, remaining cash runway, and whether additional financing or approvals are needed to complete the transaction. Historically, the stock's post-earnings moves have been driven by strategic updates rather than earnings surprises. Key risk factors include the possibility of merger delays, unexpected restructuring costs, or a cash position that proves insufficient before the deal closes.

Forward Outlook and Key Factors to Monitor

Following the earnings report, the single most important item to monitor is the status of the proposed merger with Remix Therapeutics. Management has signaled that the transaction is expected to close in the fourth quarter of 2026. Any change to that timeline, or any new regulatory or shareholder-vote conditions, would likely be the dominant driver of the stock in the near term.

Investors should also track the company's cash and cash equivalents closely. With roughly $24.2 million on hand at the end of the second quarter, the runway to reach a completed deal is a central concern. The third-quarter balance sheet will show whether cash burn has remained disciplined during the transition period.

Finally, watch for updates on remaining liabilities and wind-down costs, including lease obligations and employee-related restructuring charges. Because the company is essentially in a pre-merger holding pattern, traditional metrics like revenue growth carry little weight. Instead, clarity on deal execution, cash sufficiency, and one-time charges will define the outlook for shareholders.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations